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Background: Recent studies have identified HIV as a leading contributor to preterm delivery and its associated
morbidity and mortality. However little or no information exists in our sub-region on this subject. Identifying the
factors associated with preterm delivery in HIV positive women in our country and sub-region will not only prevent
mother to child transmission of HIV virus but will also reduce the morbidity and mortality associated with
prematurity and low birth weight. This study was designed to determine the incidence and risk factors for preterm
delivery in HIV positive Nigerians.
Method: The required data for this retrospective study was extracted from the data base of a cohort study of the
outcome of prevention of mother to child transmission at the Nigerian Institute of Medical Research, Lagos. Only
data of women that met the eligibility of spontaneous delivery after 20 weeks of gestation were included. Ethical
approval was obtained from the Institution’s Ethical Review Board.
Results: 181 women out of the 1626 eligible for inclusion into the study had spontaneous preterm delivery (11.1%).
The mean birth weight was 3.1 ± 0.4 kg, with 10.3% having LBW. Spontaneous preterm delivery was found to be
significantly associated with unmarried status (cOR: 1.7;1.52-2.57), baseline CD4 count <200 cells/mm3(cOR: 1.8;
1.16-2.99), presence of opportunistic infection at delivery (cOR: 2.2;1.23-3.57), multiple pregnancy (cOR 10.4; 4.24 – 26.17),
use of PI based triple ARV therapy (eOR 10.2; 5.52 – 18.8) in the first trimester (cOR 2.5; 1.77 – 3.52) on univariate analysis.
However after multivariate analysis controlling for potential confounding variables including low birth weight, only
multiple pregnancy (aOR: 8.6; CI: 6.73 – 12.9), presence of opportunistic infection at delivery (aOR: 1.9; CI: 1.1 – 5.7), and 1st
trimester exposure to PI based triple therapy (aOR: 5.4; CI: 3.4 – 7.8) retained their significant association with preterm
delivery.
Conclusion: The spontaneous preterm delivery rate among our cohort was 11.1%. HIV positive women with multiple
pregnancies, symptomatic HIV infection at delivery and first trimester fetal exposure to PI based triple therapy were found
to be at risk of spontaneous preterm delivery. Early booking and non-use of PI based triple therapy in the first trimester
will significantly reduce the risk of preterm delivery.
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An estimated 13 million babies are born before 37 com-
pleted weeks of gestation annually. Preterm birth is the
single most important cause of neonatal deaths and dis-
ability and directly accounts for a quarter of the global
neonatal deaths. South central Asia and Sub-Saharan Af-
rican countries are disproportionately affected by pre-
term birth and carry a greater burden of death and
disabilities attributed to preterm birth [1-4].
As achieving MDG 4 is dependent on high coverage of
evidence- based interventions to prevent preterm delivery
and to improve survival for preterm newborns, further re-
search efforts are urgently needed to better understand
context-specific pathways leading to preterm birth [2,5,6].
This is especially so in HIV high burden countries like
Nigeria where, though many interventions have been
evaluated, only very few have moderate to high quality
evidence for decreasing preterm birth [2,6-8].
Nigeria with 3.6% HIV prevalence and burden of 3.3
million contributes significantly to the global HIV bur-
den. With women accounting for about 60% of the total
HIV burden, the coexistence of HIV and pregnancy is
thus a common finding. The 2010 national surveillance
of HIV infection among pregnant women reported a
prevalence of 4.1% and estimated 210,000 HIV positive
pregnant women [9-11]. With annual birth of 56,000
HIV infected babies, Nigeria contributes approximately
10% of the global mother to child transmission of HIV
infection [9,11]. Reducing this burden by the global tar-
get of 90% by 2015 requires the prevention of the causes
and factors associated with increased mother to child
transmission of HIV infection.
Preterm delivery is one of the factors that have been
identified as a major risk factor for mother to child trans-
mission of HIV infection [12-15]. Studies have also identi-
fied HIV as a major cause of spontaneous preterm
delivery [8,12-15]. Identifying the factors associated with
spontaneous preterm delivery in HIV positive women will
not only prevent MTCT but will also reduce the morbid-
ity and mortality associated with prematurity and low
birth weight. This study was designed to determine the in-
cidence and risk factors for spontaneous preterm delivery
in HIV positive Nigerian women, with the aim of using
the information obtained to plan prevention strategies.
Method
Study setting
The study was conducted at the HIV treatment centre,
Nigerian Institute of Medical Research, Lagos. The
centre started operation in 2002 following the com-
mencement of the Federal Government of Nigeria ARV
access programme. It was included in the 25 centres
across the country to give research back up to the na-
tional ARV access programme. In 2004 it became one ofthe centers supported by the Harvard School of Public
Health (HSPH), Boston through the PEPFAR Fund. The
centre currently provides comprehensive, HIV care,
treatment and support for 16, 679 patients (64.6% are
women). Sixty five percent of the patients come from
Lagos and the rest from the other 5 states of southwes-
tern Nigeria as well as from north-central, south-south
and south-eastern Nigeria. A little over 0.025% comes
from the neigbouring West African countries. No user
fee is charged at the centre. Patients are enrolled into
the HIV treatment programme following a referral from
the HIV Counseling and Testing Centre, Nigerian Insti-
tute of Medical Research Lagos or transfer from other
government of Nigeria HIV treatment centres.
HIV positive pregnant women are seen and registered
for PMTCT services at the Wednesday PMTCT clinic.
While the antenatal and postnatal services, including in-
fant post exposure prophylaxis are provided by the
centre, the intrapartum care is provided in collaboration
with Lagos University Teaching Hospital, Idi Araba;
Lagos State University Teaching Hospital, Ikeja; General
Hospitals Surulere, Apapa, Ikorodu; Havana Specialist
Hospital Surulere; Rao Specialist Hospital Surulere, and
a number of Catholic mission and private hospitals.
Health workers from these centres have been trained on
intrapartum care of HIV positive mothers either by our
centre, the state or national HIV programme. The
mothers are referred to any of the centres nearest to
their place of residence at 36 weeks or as soon as pos-
sible with detailed information about their chosen mode
of delivery, infant feeding choice, and Viral Load and
CD4 count results. Infant post exposure drug and
mothers ARV drugs are also given to the women. After
their delivery at the facility, the women are referred back
to our centre at 2 weeks post-delivery with a completed
Case Record Form (CRF) designed specifically to capture
all delivery related information. Information on the CRF
is used to complete the postnatal data base. The home
based care team contacts any mother who does not re-
port back to centre at 2 weeks post expected date of de-
livery to ascertain the reasons for the default.
Study population
All HIV positive women enrolled into our PMTCT
programme between July 2004 and June 2010 that met
the eligibility criteria were included into the study. Eligi-
bility criteria for this study was based on the WHO def-
inition of viability, that is a birth weight of ≥ 500 g and
born at ≥ 20 weeks of gestation. Gestational age was esti-
mated by the number of days between the first day of
the last menstrual period (LMP) and date of birth
expressed in completed weeks after LMP. A preterm
birth was defined as births of infants occurring at less
than 37 completed weeks of gestation. Cases of preterm
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excluded. Births without information on vital status,
birth weight and gestational age were excluded.
Antiretroviral regimen used during the study period
Antiretroviral drug regimen used during the study
period changed over time as a result of the change in na-
tional PMTCT guidelines. The regimen changed thrice
between July 2004 and June 2010. From July 2004 till
March 2006, because of non-availability of widely
accepted Nigerian national PMTCT guideline, HAART
based regimen was used for PMTCT except for women
who presented in labour who were given single dose
Nevirapine with Combivir (Zidovudine and Lamivudine)
tail of seven days. Between March 2006 and December
2009, the then national PMTCT guideline was nationally
adopted and our centre switched to the dictates of the
guideline. Triple ARV therapy (HAART) was used only
for women eligible for it based on the clinical stage of
their HIV disease or CD4 count less than 200 cell/mm3.
Those with CD4 count above 200cells/mm3 were placed
on ART prophylaxis of either monotherapy (Zidovudine)
or dual therapy (Zidovudine + Lamivudine) depending
on the gestational age at booking. From January 2010 we
reverted back to triple ARV based regimen for all
women as the national guideline was revised in line with
WHO recommendation. While NNRTI based HAART
was given to women with CD4 counts less than 350
cells/mm3, PI based HAART was prescribed for women
with CD4 cell count of ≥ 350 cells/mm3.
Data management
Information on all HIV positive pregnant women who
completed PMTCT services during the study period and
met the eligibility criteria was extracted from the centres
PMTCT Data base which was collected prospectively.
For each birth we extracted information on the date of
birth, booking status, maternal age and parity, height
and weight, marital status, previous obstetric history,
estimated gestational age, birth weight, sex and vital sta-
tus of the baby at birth and whether the infant was a sin-
gle or multiple delivery. Information on CD4 count, viral
load, opportunistic infection status at delivery, type of
ARV drug regimen, time of intiation of triple ARV and
duration was also collected.
A mother was considered as ‘booked’ if both her preg-
nancy and HIV status were assessed; laboratory results
reviewed and decision taken on the management of her
pregnancy. Social status classification by Olusanya and
colleagues [16] which was validated for use for the classi-
fication of social status of Nigerian women was used. In
this system women were classified to belong to one of 5
social classes based on a combination of their educational
status and the occupation of their spouse (Class I – V).While classes I and II denote upper social class, classes III
and IV, and class V represent middle and lower social
classes respectively.
A total of 1843 pregnant HIV positive women booked
for PMTCT services during the period with 96.2%
(1789) completing the PMTCT services. A total of 1812
babies were delivered by the 1789 women, comprising of
1766 singleton and 23 twin deliveries. One hundred and
sixty three cases were excluded from the 1789 (9.3%)
births because gestational ages were less than 20 weeks
(11.0%), information on birth weight, and gestational age
was missing because they delivered outside a hospital
facility (34.4%), no vital status information (16.6%),
baby weighed less than 500 g despite the LMP date
given by the women (14.4%), did not give consent for
their data to be uploaded (1.8%), viral load and CD4
results could not be traced (19.0%) and estimated gesta-
tional age above 46 weeks (2.5%) but birth weights less
than 2.5 kg.
Frequency distributions were generated and univariate
analysis using relevant statistics was performed to iden-
tify factors associated with spontaneous preterm deliv-
ery. Multivariate logistic regression was used to identify
independent risk factors for preterm births while con-
trolling for potential confounders including low birth
weight, stage of HIV disease, reproductive tract infection
and medical disorders. Variables were entered into the
model if their P value on univariate analysis was 0.25 or
less. The variable with the strongest association in the
univariate model was estimated first, followed by others
in descending order. In the analysis, the comparison
group was term deliveries (a birth at 37–42 completed
weeks of gestation). P < 0.05 was considered to be statis-
tically significant. Odds Ratios (OR) and 95% Confidence
Intervals (CI) for the OR were also calculated.
Ethical issues
Approval for the study was obtained from the Institu-
tional Review Board, Nigerian Institute of Medical Re-
search, Lagos Nigeria. Written informed consent was
obtained from all women for the use of their data for
study. However women who declined consent to partici-
pate in the study were provided care but excluded from
research. The clinic patients are organized into an inde-
pendent support group of people living with HIV (Posi-
tive Life Organization of Nigeria) that ensures that
patients are not stigmatized and discriminated against.
This group ensures that no patient is denied requisite
care because of failure to participate in any of our stud-
ies including this study.
Result
One thousand six hundred and twenty six women com-
pleted the PMTCT programme and fulfilled the
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bies were delivered by the 1626 women; 46 of whom
were products of twin gestation. The gestational age at
booking ranged from 6 to 40 weeks with a mean of
28.6 ± 8.7 weeks. While three hundred and twenty six
(20.1%) women registered for PMTCT services during
the first trimester, 509 (31.3%) and 791(48.6%) registered
during the second and third trimesters respectively.
Eight hundred and forty seven (52.1%) of 1626 women
received HAART based regimen (Triple ARV therapy),
out of which only 3.5% (57) were on PI based HAART
regimen. Three hundred and nine (36.5%) of the 847
women on triple ARV therapy received HAART in the 1st
trimester because they were either on it before pregnancy
(212; 68.6%), or started on it for their own disease or for
PMTCT prophylaxis (97; 31.4%). The remaining 538
(63.5%) women on triple regimen were commenced on it
during second (288; 34.0%) and third (250; 29.5%) trime-
sters respectively. In all 635 (74.9%) of the women that
received triple ARV therapy were started on it after book-
ing. Of the 779 (47.9%) women that received non triple
ARV regimen (single or dual therapy), majority were on
Lamivudine + Zidovudine combination (63.7%) and the
remaining women received either Zidovudine only regi-
men (29.4%) or single dose nevirapine in labour (7.9%).Table 1 Sociodemographic characteristics of the HIV positive
Factors Preterm Cases (%) No Preterm
N=181 N=144
Age (years)
• <20 7 (3.9) 43 (3.0)
• 20 – 35 151 (83.4) 1243 (86.0)
• >35 23 (12.7) 159 (11.0)
Parity
• 0 54 (29.8) 316 (21.9)
• 1 – 2 71 (39.3) 541 (37.4)
• >2 56 (30.9) 588 (40.7)
Marital status
• Married 145 (80.1) 1261 (87.3)
• Not married 36 (19.9) 184 (12.7)
Work status
• Working 138 (76.2) 1068 (73.9)
• Not working 43 (23.8) 374 (26.1)
Stress at work
• Stressful 90 (65.2) 614 (57.3)
• Not stressful 48 (34.8) 457 (42.7)
Social Class [16]
• I & II 20 (11.0) 146 (10.1)
• III 49 (27.1) 415 (28.7)
• IV & V 112 (61.9) 884 (61.2)One hundred and eighty one of the eligible 1626
women delivered before 37 completed weeks; a spontan-
eous preterm delivery rate of 11.1% (95% CI: 8.31- 19.6).
Table 1 shows the relationship between the women’s
sociodemographic characteristics and preterm labour.
Significant association were only found between women
who were not currently married (cOR: 1.7; 95 CI: 1.12-
2.57), or engaged in stressful work (cOR :1.4; CI: 1.01-
2.06) and preterm delivery.
The effect of biological and anthropometric factors of
CD4 count, viral load, BMI, presence of opportunistic
and reproductive tract infections at delivery on preterm
delivery is summarized in table 2. There was significant
association between all the factors and preterm delivery,
except for HIV viral load which showed no association
with preterm delivery.
Table 3 shows the relationship between the women’s
past obstetric and gynaecological history and preterm
delivery. None of the variables showed significant associ-
ation with preterm delivery.
Table 4 shows the association between current obstetric
and HIV treatment history of the women and preterm de-
livery. Multiple pregnancy (cOR 10.4; 4.24 – 26.7), use of
PI based regimen (cOR 10.2; CI: 5.52-18.8), initiation of
triple regimen in the first trimester (cOR:2.5;CI:1.77-3.52)pregnant women (n= 1626)
(%) P value OR 95% CI
5
0.63 1.3 0.54 – 3.57
1.0 1.0
0.55 1.2 0.72 – 1.94
0.20 1.3 0.87 – 1.94
1.0 1.0
0.10 0.7 0.49 – 1.07
1.0 1.0
<0.05 1.7 1.12 – 2.57
0.59 1.12 0.77–1.64
1.0 1.0
0.04 1.4 1.01 – 2.06
1.0 1.0
0.70 0.70 0.48 – 1.56
1.0 1.0
0.87 0.9 0.54 – 1.59
Table 2 Biological and anthropometric characteristics of the HIV positive pregnant women (n= 1626)
Factors Preterm Cases (%) No Preterm (%) P value OR 95% CI
N=181 N=1445
CD4 level
• <200 47 (26.0) 265 (18.3) 0.008 1.8 1.16 – 2.99
• 200 – 350 49 (27.1) 410 (28.4) 0.36 1.3 0.79 – 2.00
• 351–500 40 (22.0) 421 (29.1) 1.0 1.0
• >500 45 (24.9) 349 (24.2) 0.22 1.4 0.83 – 2.18
Viral load
• <1000 79 (43.6) 741 (51.3) 1.0 1.0
• 1000 – 10,000 48 (26.5) 322 (22.2) 0.10 1.4 0.94 – 2.08
• >10,000 54 (29.9) 382 (26.4) 0.16 1.3 0.90 – 1.94
Body Mass Index
• <18.50 12 (6.7) 101 (7.0) 0.94 0.96 0.46 – 1.83
• 18.50 - 24.99 98 (54.1) 791 (54.8) 1.0 1.0
• >= 25 71 (39.2) 553 (38.2) 0.89 1.04 0.74 – 1.45
Opportunistic Infection at delivery
• Present 21 (11.6) 85 (5.9) 0.01 2.1 1.23 – 3.57
• Absent 160 (88.4) 1360 (94.1) 1.0 1.0
Reproductive tract infection at delivery
Present 13 (7.2) 51 (3.5) 0.03 2.1 1.07–4.11
Absent 168 (92.8) 1394 (96.5) 1.0 1.0
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were found to be significantly associated with preterm
delivery . Medical disorders were not found to be asso-
ciated with preterm delivery in this cohort (cOR:0.97;
CI: 0.44-2.04).
After adjustment for potential confounding variables
in multivariate logistic regression including but notTable 3 Past Obstetric and Gynaecological characteristics of t
Factors Preterm Cases (%) No
N=181
Induced abortion history
• 0 61 (33.0) 56
• 1 64 (35.0) 47
• ≥ 2 56 (30.0) 40
Spontaneous abortion
• 0 145 (80.1) 117
• 1 27 (14.9) 19
• ≥ 2 9 (5.7) 9
Preterm delivery
• Yes 9 (5.0) 4
• No 172 (95.0) 140
Operative vaginal delivery
• Yes 11 (6.1) 5
• No 170 (97) 138limited to controlling for low birth weight, stage of HIV
disease, reproductive tract infection and medical disor-
ders, spontaneous preterm delivery in HIV positive
women were found to be associated with stressful work
(aOR 1.2; CI:1.05- 4.8), OIs (aOR: 1.9; CI: 1.1 – 5.7),
multiple pregnancy (aOR: 8.6; CI: 6.73 – 12.9) and 1st
trimester use of PI based regimen (aOR: 5.4;CI: 3.4-7.8).he HIV positive pregnant women (n =1626)
Preterm (%) P value OR 95% CI
N=1445
6 (39.0) 1.0 1.0
6 (32.0) 0.28 1.3 0.85 – 1.84
3 (27.0) 0.23 1.3 0.86 – 1.93
5 (81.3) 1.0 1.0
8 (10.3) 0.7 1.1 0.70 – 1.74
2 (4.9) 0.6 0.8 0.37 – 1.66
1 (2.8) 0.8 1.8 0.80 – 3.91
4 (97.2 ) 1.0 1.0
6 (3.9) 0.2 1.0 1.0
9 (96.1) 1.6 0.78 –3.24
Table 4 Current Obstetric and HIV treatment characteristics of the HIV positive pregnant women (n =1626)
Factors Preterm Cases (%) No Preterm (%) P value OR 95% CI
N=181 N=1445
Bleeding in pregnancy
• Yes 17 (9.4) 137 (2.6) 0.92 1.1 0.60 – 1.85
• No 164 (90.6) 1408 (97.4) 1.0 1.0
Sex of baby
• Male 81 (44.8) 752 (51.7) 0.06 0.7 0.53 – 1.01
• Female 103 (55.2) 703 (48.3) 1.0 1.0
Multiple pregnancy
• Yes 13 (7.1) 10 (0.7) 0.00 10.4 4.24 – 26.17
• No 178 (92.9) 1435 (99.3) 1.0 1.0
ARV Regimen used for PMTCT
• Non PI based HAART Regimen 80 (44.2) 710 (49.1) 0.61 1.11 0.78–1.57
• PI Based HAART Regimen 29 (16.0) 28 (1.9) 0.000 10.2 5.52–18.8
• Non HAART Regimen 72 (39.8) 707 (48.9) 1.0 1.0
Duration of ARV drugs
• <8weeks 47 (32.4) 307 (27.1) 0.42 1.2 0.79 – 1.82
• 8-13 weeks 67 (46.2) 525 (46.4) 0.42 0.8 0.51 – 1.30
• >13 weeks 31 (21.4) 299 (26.5) 1.0 1.0
Period HAART commenced
• 1st trimester 96 (53.2) 230 (31.2) 0.00 2.5 1.77 – 3.52
• After 1st trimester 85 (46.8) 508 (68.8) 1.0 1.0
Medical disorders
• Present 9 (5.0) 74 (5.1) 0.92 0.97 0.44 – 2.04
• Absent 172 (95.0) 1371 (94.9) 1.0 1.0
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While several studies elsewhere have reported on the
prevalence and risk factors for preterm delivery and low
birth weight in HIV positive pregnant women, no infor-
mation on the subject currently exists from our sub re-
gion [6-11]. The closest information are reports from
the central African countries of Cameroun and Rwanda
[6-8]. In addition, the sample size for the two studies
from Cameroun and Rwanda were rather small making
generalization to Nigeria with the 2nd highest global
HIV burden difficult. In this study we determined the in-
cidence and risk factors of preterm delivery using infor-
mation extracted from prospectively collected data of
1626 HIV positive pregnant women over a 6-year period.
Information obtained will assist us and others within our
sub region or elsewhere to plan strategies to control and
prevent preterm delivery and its associated morbidity
and mortality in HIV positive pregnant women.
The preterm delivery rate of 11.1% among the HIV
positive pregnant women in this study was similar to
13.5% and 13.6% reported by Towsend and colleagues
[11] from United Kingdom and Taguebue and colleagues
[6] from Cameroun but much lower than 23.5% reportedby Dreyfuss and colleagues from Tanzania, East Africa
[17]. The relatively low rate of the preterm delivery in
our cohort may be related to the fact that most of our
patients were diagnosed early as part of routine volun-
tary HIV testing during antenatal care, allowing for early
initiation of treatment of opportunistic infection which
could trigger preterm contractions. In addition a signifi-
cant number was already on treatment before present
pregnancy and only a small proportion of them were on
PI based HAART(3.5%) which has been shown to be
associated with preterm delivery. The cohorts from Tan-
zania had a high rate of nutritional deficiency and were
in more advanced stages of HIV disease compared to
our cohort [6] and thus a high rate of over 23%.
The preterm rate was however significantly higher
than rates of 5.8% and 8.5% reported among Nigeria
women of unknown HIV status by Etuk [6] and Chike
Obi [7] from Nigeria . This higher rate may be attribut-
able to HIV, confirming the findings of the association
between HIV and preterm delivery.
In previous studies several factors were identified as
risk factors for the development of preterm delivery in
HIV positive pregnant women [6-11], However only
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tunistic infection at delivery and first trimester exposure
to PI based triple ARV therapy were found to be asso-
ciated with preterm delivery in this cohort. Our study
utilized a larger sample size and methodologically col-
lected data and thus may have been able to remove the
background noise that may have influenced the result of
other studies. In addition those studies were from
regions with different HIV epidemiology. While the HIV
incidence is in single digits in west Africa, in east Africa
it is in double digits and the epidemic there is more
matured. The viral subtypes and genotypes are also quite
different.
The most important predictor of preterm delivery in
this cohort was multiple pregnancies (aOR: 8.6; CI: 6.73 –
12.9). Though this finding is similar to findings of Tague-
bue and colleagues from central Africa [6], studies from
UK [11] and East Africa [9] did not identify multiple
pregnancies as contributing to preterm delivery in HIV
positive women. It is also important to note that in our
earlier study among HIV negative population from the
same region of Nigeria where the current study was con-
ducted, we identified multiple pregnancies as a major risk
factor for preterm delivery [5]. Our study thus showed
that irrespective of HIV status, multiple pregnancies
remains a significant cause of preterm delivery in our
country. Women with multiple pregnancies tend to de-
velop preterm delivery because of uterine over distention
(malpresentation, polyhydramionos), and premature rup-
ture of membrane, antepartum haemorrhage and intra-
uterine growth retardation [1,4,5], which may trigger
uterine contractions.
Opportunistic infections at delivery (aOR: 1.9; CI: 1.1 –
5.7), stressful work (aOR 1.2; CI: 1.05- 4.8) and first tri-
mester exposure to PI based HAART (aOR: 2.4; CI:
1.07 – 3.15) were the other factors shown to be asso-
ciated with preterm delivery in our cohort. While the
association of the presence of OIs and stressful work
with preterm delivery in HIV positive women seems ob-
vious, that of first trimester PI based HAART exposure
was not immediately obvious. However it is in keeping
with previous reports which showed that PI based
HAART is associated with preterm delivery [11]. It is
also important to state that while other studies were not
able to associate the period of HAART and preterm de-
livery we were able to show that only first trimester PI
based HAART exposure and not Non PI based HAART
or its duration was associated with preterm delivery.
There has been ongoing debate on the role of PI based
regimen on preterm delivery rate [18-26]. While some
studies reported an association between PI use and pre-
term delivery [20-23], others have reported no associ-
ation [24,25] or have been underpowered to detect a
modest increase in preterm deliveries [26]. The resultsof this study supports other studies that linked preterm
delivery to use of PI based regimen [20-24]. In our study
we not only used a large sample size but also controlled
for possible confounders. Our study was also sufficiently
powered to detect a two times risk of developing pre-
term delivery in pregnant HIV positive women who were
exposed to first trimester PI based HAART.
The presence of reproductive tract infection at delivery
which was found to be associated with preterm birth at
univariate analysis did not retain its significant associ-
ation with preterm delivery after controlling for the ef-
fect of co-morbidity of opportunistic infection. In
addition the small proportion of women with reproduct-
ive tract infection at delivery in this cohort may have
contributed to loss of significance. As a result of the
great aversion for caesarean section among Nigerian
women [27], we actively screen for and treat vaginal in-
fection before referral at 36 weeks even when the
women have been previously treated. The active screen-
ing and prompt treatment of reproductive tract infection
ensured that only few women still had reproductive tract
infection at delivery.
Though our study tried to eliminate the weakness of
other previous studies, we had the limitation of its being
a retrospective study. However the data used for this
analysis, though retrospectively assembled is part of a
methodologically collected data base of a PMTCT follow
up study in our facility. Data used were extracted from a
prospectively collected data using case record form
designed for the PMTCT follow up study thus ensuring
the quality and completeness of data used in this study.
Conclusion
This study shows that HIV positive Nigerian women are
at increased risk of preterm delivery, more especially so
in women with multiple gestations, opportunistic infec-
tion close to delivery, who engaged in stressful work and
commenced on PI based HAARTduring the first
trimester.
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